1-(4-溴苄基)-1-(4-甲氧基苯基)肼 | 176045-80-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 1-(4-溴苄基)-1-(4-甲氧基苯基)肼
• 中文别名: 1-(4-溴苄基)-1-(4-甲氧基苯基)肼盐酸盐
• 英文名称: N-(4-bromobenzyl)-N-(4-methoxyphenyl)-hydrazine
• 英文别名: 1-(4-Bromobenzyl)-1-(4-methoxyphenyl)hydrazine；1-[(4-bromophenyl)methyl]-1-(4-methoxyphenyl)hydrazine
• CAS: 176045-80-0
• 化学式: C₁₄H₁₅BrN₂O
• 分子量: 307.19
• InChiKey: VNMAXLTXXYCFHZ-UHFFFAOYSA-N

物化性质

• 沸点：
  445.0±35.0 °C(Predicted)
• 密度：
  1.425

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  18
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  38.5
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2928000090

反应信息

• 作为反应物：
  描述：

  1-(4-溴苄基)-1-(4-甲氧基苯基)肼 在 盐酸 、 二异丁基氢化铝 、 溶剂黄146 、 酒石酸 作用下， 生成 (1-(4-Bromobenzyl)-5-methoxy-2-methyl-1H-indol-3-yl) acetaldehyde
  参考文献：
  名称：

  Synthesis and biological evaluation of both enantiomers of L-761,000 as inhibitors of cyclooxygenase 1 and 2

  摘要：

  Both enantiomers of L-761,000 were prepared and evaluated for their cyclooxygenase activities.

  DOI：

  10.1016/0960-894x(96)00101-1
• 作为产物：
  描述：

  4-甲氧基苯肼盐酸盐 、 对溴溴苄 在 三乙胺 作用下， 以 甲苯 为溶剂， 反应 3.0h， 生成 1-(4-溴苄基)-1-(4-甲氧基苯基)肼
  参考文献：
  名称：

  WO2008/67566

  摘要：

  公开号：

文献信息

• 5-Lipoxygenase-Activating Protein Inhibitor
  申请人：SCHAAB Kevin Murray

  公开号：US20090291981A1

  公开（公告）日：2009-11-26

  Described herein is the FLAP inhibitor 3-[3-tert-butylsulfanyl-1-[4-(6-ethoxy-pyridin-3-yl)-benzyl]-5-(5-methyl-pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic acid, or a pharmaceutically acceptable salt thereof. Also described are methods of preparing the FLAP inhibitor, or a pharmaceutically acceptable salt thereof, including solvates, and polymorphs thereof. Also described herein are pharmaceutical compositions suitable for administration to a mammal that include the FLAP inhibitor, or a pharmaceutically acceptable salt thereof, and methods of using such pharmaceutical compositions for treating respiratory conditions or diseases, as well as other leukotriene-dependent or leukotriene mediated conditions or diseases.

  描述了一种FLAP抑制剂：3-[3-叔丁基硫基-1-[4-(6-乙氧基-吡啶-3-基)-苄基]-5-(5-甲基-吡啶-2-基甲氧基)-1H-吲哚-2-基]-2,2-二甲基丙酸，或其药用可接受盐。还描述了制备该FLAP抑制剂的方法，或其药用可接受盐，包括水合物和其多晶型。还描述了适合给予哺乳动物的药物组合物，包括FLAP抑制剂，或其药用可接受盐，以及使用此类药物组合物治疗呼吸系统疾病或疾病的方法，以及治疗其他白三烯依赖性或白三烯介导的条件或疾病的方法。
• Novel Processes
  申请人：Crawford Claire Frances

  公开号：US20120220779A1

  公开（公告）日：2012-08-30

  The present invention provides processes useful for preparing 5-lipoxygenase activating protein (FLAP) inhibitors and their intermediates. In particular, processes for preparing 3-[3-(tert-butylsulfanyl)-1-[4-(6-ethoxy-pyridin-3-yl)benzyl]-5-(5-methyl-pyridin-2-yl-methoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic acid, the anhydrous Form C polymorph of sodium 3-[3-(tert-butylsulfanyl)-1-[4-(6-ethoxy-pyridin-3-yl)benzyl]-5-(5-methyl-pyridin-2-yl-methoxy)-1H-indol-2-yl]-2,2-dimethyl-propionate, and intermediates useful in said processes are provided.

  本发明提供了用于制备5-脂氧合酶激活蛋白（FLAP）抑制剂及其中间体的有用过程。具体来说，提供了用于制备3-[3-(叔丁基硫基)-1-[4-(6-乙氧基吡啶-3-基)苄基]-5-(5-甲基吡啶-2-基甲氧基)-1H-吲哚-2-基]-2,2-二甲基丙酸，无水Form C晶型的钠盐3-[3-(叔丁基硫基)-1-[4-(6-乙氧基吡啶-3-基)苄基]-5-(5-甲基吡啶-2-基甲氧基)-1H-吲哚-2-基]-2,2-二甲基丙酸酯，以及在该过程中有用的中间体。
• 5-LIPOXYGENASE ACTIVATING PROTEIN (FLAP) INHIBITOR
  申请人：REWOLINSKI Melissa Virginia

  公开号：US20100075934A1

  公开（公告）日：2010-03-25

  Described herein are methods for the synthesis of 3-[5-(pyridin-2-ylmethoxy)-3-(2-methyl-2-propylthio)-1-[4-(2-methoxypyridin-5-yl)benzyl]-indol-2-yl]-2,2-dimethyl-propionic acid, pharmaceutically acceptable salts, pharmaceutically acceptable solvates thereof. Also described are pharmaceutical compositions suitable for oral administration to a mammal that include, as well as methods of using such oral pharmaceutical compositions for treating respiratory conditions or diseases, as well as other leukotriene-dependent or leukotriene mediated conditions or diseases.

  本文描述了一种合成3-[5-(吡啶-2-基甲氧基)-3-(2-甲基-2-丙基硫)-1-[4-(2-甲氧基吡啶-5-基)苯基]-吲哚-2-基]-2,2-二甲基丙酸及其药学上可接受的盐和可接受的溶剂的方法。还描述了适用于口服给哺乳动物的药物组合物，以及使用这种口服药物组合物治疗呼吸道疾病或疾病以及其他白三烯依赖性或白三烯介导的疾病或疾病的方法。
• 5-LIPOXYGENASE-ACTIVATING PROTEIN INHIBITOR
  申请人：Schaab Kevin Murray

  公开号：US20110160249A1

  公开（公告）日：2011-06-30

  A pharmaceutically acceptable salt comprising 3-[3-tert-butylsulfanyl-1-[4-(6-ethoxy-pyridin-3-yl)-benzyl]-5-(5-methyl-pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionate as the anion and a cation selected from Na + , K + , Li + , Ca 2+ , NH 4 + , the protonated form of dicyclohexylamine, the protonated form of N-methyl-D-glucamine, the protonated form of tris(hydroxymethyl)methylamine, the protonated form of arginine, and the protonated form of lysine is disclosed, along with formulations and methods of using the same.

  本发明涉及一种药物可接受的盐，其包括3-[3-叔丁基磺酰基-1-[4-(6-乙氧基吡啶-3-基)-苄基]-5-(5-甲基吡啶-2-基甲氧基)-1H-吲哚-2-基]-2,2-二甲基丙酸根离子和从Na+、K+、Li+、Ca2+、NH4+、二环己基胺质子化形式、N-甲基-D-葡萄糖胺质子化形式、三羟甲基甲基胺质子化形式、精氨酸质子化形式和赖氨酸质子化形式中选择的阳离子，以及使用它们的制剂和方法。
• From indomethacin to a selective COX-2 inhibitor: Development of indolalkanoic acids as potent and selective cyclooxygenase-2 inhibitors
  作者：W.C. Black、C. Bayly、M. Belley、C.-C. Chan、S. Charleson、D. Denis、J.Y. Gauthier、R. Gordon、D. Guay、S. Kargman、C.K. Lau、Y. Leblanc、J. Mancini、M. Ouellet、D. Percival、P. Roy、K. Skorey、P. Tagari、P. Vickers、E. Wong、L. Xu、P. Prasit

  DOI：10.1016/0960-894x(96)00100-x

  日期：1996.3

  A series of potent and highly selective cyclooxygenase-2 inhibitors have been prepared by replacing the benzoyl group of indomethacin with a 4-bromobenzyl group, and by extending the acetic acid side chain. These compounds show anti-inflammatory activity in rats with no evidence of GI toxicity, even at high doses.